Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 218

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 218
---
    — |

The accompanying notes are an integral part of these consolidated financial statements.

F-11

IRIS PARENT HOLDING CORP. CONSOLIDATED STATEMENTS OF OPERATIONS

| ​                                                       
 ​                                                       | ​ 
 ​ | ​                               
 For the year ended December 31, 
 ​                               |     ​ 
  2024 | ​ | ​ |     ​ 
  2023 |
|:--------------------------------------------------------|:--|:--------------------------------|------:|:--|:--|------:|
| Franchise tax expense                                   | ​ | $                               |   405 | ​ | $ |   378 |
| Loss from operations                                    | ​ |                                 |  -405 | ​ |   |  -378 |
| ​                                                       | ​ | ​                               |     ​ | ​ | ​ |     ​ |
| Net loss                                                | ​ | $                               |  -405 | ​ | $ |  -378 |
| ​                                                       | ​ | ​                               |     ​ | ​ | ​ |     ​ |
| Weighted average shares outstanding - basic and diluted | ​ |                                 |   100 | ​ |   |   100 |
| ​                                                       | ​ | ​                               |     ​ | ​ | ​ |     ​ |
| Basic and diluted net loss per share                    | ​ | $                               | -4.05 | ​ | $ | -3.78 |

The accompanying notes are an integral part of these consolidated financial statements.

F-12

IRIS PARENT HOLDING CORP. CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDER’S EQUITY FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

| ​                 
 ​                 
 ​                 | ​ 
 ​ |            ​ 
 Common Stock 
       Shares | ​ | ​      
 Amount | ​ | ​ | ​               
 Additional Paid 
 in Capital      |  ​ | ​ | ​                  
 Stock Subscription 
 Receivable         |   ​ | ​ | ​           
 Accumulated 
 Deficit     |    ​ | ​ | ​             
 Stockholder’s 
 Equity        |    ​ |
|:------------------|:--|-------------:|:--|:-------|:--|:--|:----------------|---:|:--|:-------------------|----:|:--|:------------|-----:|:--|:--------------|-----:|
| December 31, 2022 | ​ |          100 | ​ | $      | — | ​